Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.76 |
| ▸ | CASP7 | P55210 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | MDM4 | O15151 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.73 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.73 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14360682 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL678540 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL18994243 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL11457420 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL18265875 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL24897190 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL18575846 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL22871870 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL22855545 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 | |
| SCHEMBL15976038 | 1.00 | VDR (1.00) | VDRUSP2ST6GAL1ABCC4CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278992-B2 | Function-selective vitamin D receptor agonist | NIHON UNIVERSITY (JP) | 2016-03-08 | — | — | US | claimed |
| CN-119716080-A | Radioactive enteritis differential metabolite marker based on fecal metabonomics, screening method and application thereof | 中山大学附属第六医院 | 2025-03-28 | — | — | CN | disclosed |
| US-20230174988-A1 | METHODS FOR INDUCING BILE ACID SULFOTRANSFERASE SULT2A FOR TREATING METABOLIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2021226447-A1 | METHODS FOR INDUCING BILE ACID SULFOTRANSFERASE SULT2A FOR TREATING METABOLIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021033766-A1 | LITHOCHOLIC ACID DERIVATIVE HAVING VITAMIN D ACTIVITY | 国立大学法人お茶の水女子大学 | 2021-02-25 | — | — | WO | disclosed |
| US-10889611-B2 | Sialyltransferase inhibitors and uses thereof | ACADEMIA SINICA (TW) | 2021-01-12 | — | — | US | disclosed |
| WO-2017035501-A1 | SIALYLTRANSFERASE INHIBITORS AND USES THEREOF | ACADEMIA SINICA (TW) | 2017-03-02 | — | — | WO | disclosed |
| US-9278992-B2 | Function-selective vitamin D receptor agonist | NIHON UNIVERSITY (JP) | 2016-03-08 | — | — | US | disclosed |
| EP-2081949-B1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2163557-B1 | FUNCTION-SELECTIVE VITAMIN D RECEPTOR AGONIST | UNIV NIHON (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-4215045-A | 123m Te-Labeled biochemicals and method of preparation | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | VDR 131/4885USP2 1764/4885ST6GAL1 4661/4885 |
| US-10889611-B2 | Sialyltransferase inhibitors and uses thereof | ST6GAL1, NEU1, GALNT1 | VDR 3873/4885USP2 1906/4885ST6GAL1 1/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | VDR 991/4885USP2 1590/4885ST6GAL1 3307/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | VDR 848/4885USP2 2216/4885ST6GAL1 4699/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | VDR 95/4885USP2 1697/4885ST6GAL1 3757/4885 |
| US-20230174988-A1 | METHODS FOR INDUCING BILE ACID SULFOTRANSFERASE SULT2A FOR TREATING METABOLIC DISORDERS | CYP7A1, CYP27A1, CYP7B1 | VDR 12/4885USP2 1324/4885ST6GAL1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.